Libbey S. O′Farrell

1.2k total citations · 2 hit papers
17 papers, 648 citations indexed

About

Libbey S. O′Farrell is a scholar working on Molecular Biology, Pharmacology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Libbey S. O′Farrell has authored 17 papers receiving a total of 648 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Libbey S. O′Farrell's work include Diabetes Treatment and Management (6 papers), Pharmacology and Obesity Treatment (5 papers) and Adipose Tissue and Metabolism (5 papers). Libbey S. O′Farrell is often cited by papers focused on Diabetes Treatment and Management (6 papers), Pharmacology and Obesity Treatment (5 papers) and Adipose Tissue and Metabolism (5 papers). Libbey S. O′Farrell collaborates with scholars based in United States, Germany and Japan. Libbey S. O′Farrell's co-authors include Tamer Coşkun, Axel Haupt, Shweta Urva, Daniel A. Briere, Corina Loghin, Charles Benson, Andrew C. Adams, Susan L. DuBois, Jorge Alsina‐Fernandez and Hongchang Qu and has published in prestigious journals such as Cell, Cell Metabolism and Diabetes.

In The Last Decade

Libbey S. O′Farrell

16 papers receiving 633 citations

Hit Papers

LY3437943, a novel triple glucagon, GIP, and GLP-1 recept... 2022 2026 2023 2024 2022 2025 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
    2022 180 citations Tamer Coşkun, Shweta Urva et al. Cell Metabolism profile →
  2. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
    2025 18 citations Éric Ravussin, Guillermo Sánchez‐Delgado et al. Cell Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Libbey S. O′Farrell United States 10 299 256 252 151 120 17 648
Joseph R. Chabenne United States 7 251 0.8× 197 0.8× 164 0.7× 75 0.5× 147 1.2× 9 496
Sirel Gurbuz United States 5 677 2.3× 341 1.3× 235 0.9× 430 2.8× 192 1.6× 7 921
Joanna Van United States 5 698 2.3× 267 1.0× 342 1.4× 275 1.8× 273 2.3× 6 938
Sarah Farr Canada 13 257 0.9× 135 0.5× 193 0.8× 53 0.4× 160 1.3× 17 582
R. Troke United Kingdom 7 361 1.2× 222 0.9× 176 0.7× 134 0.9× 203 1.7× 8 669
Elizabeth Zieliński United States 7 127 0.4× 287 1.1× 175 0.7× 49 0.3× 131 1.1× 12 579
Lene Jessen Denmark 11 450 1.5× 343 1.3× 213 0.8× 105 0.7× 399 3.3× 13 798
Todd M. Suter United States 9 270 0.9× 283 1.1× 258 1.0× 121 0.8× 119 1.0× 12 740
Jennifer Athanacio United States 9 219 0.7× 192 0.8× 130 0.5× 77 0.5× 114 0.9× 9 554
Ann-Marie Richard United States 10 122 0.4× 246 1.0× 254 1.0× 59 0.4× 169 1.4× 11 537

Countries citing papers authored by Libbey S. O′Farrell

Since Specialization
Citations

This map shows the geographic impact of Libbey S. O′Farrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libbey S. O′Farrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libbey S. O′Farrell more than expected).

Fields of papers citing papers by Libbey S. O′Farrell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Libbey S. O′Farrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libbey S. O′Farrell. The network helps show where Libbey S. O′Farrell may publish in the future.

Co-authorship network of co-authors of Libbey S. O′Farrell

This figure shows the co-authorship network connecting the top 25 collaborators of Libbey S. O′Farrell. A scholar is included among the top collaborators of Libbey S. O′Farrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Libbey S. O′Farrell. Libbey S. O′Farrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ravussin, Éric, Guillermo Sánchez‐Delgado, Corby K. Martin, et al.. (2025). Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metabolism. 37(5). 1060–1074.e4. 18 indexed citations breakdown →
2.
Briere, Daniel A., Hongchang Qu, Katherine Lansu, et al.. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 102. 102271–102271. 4 indexed citations
3.
4.
Roell, William C., Tamer Coşkun, Teayoun Kim, et al.. (2024). Characterization of LY3324954 a long-acting glucagon-receptor agonist. Molecular Metabolism. 91. 102073–102073. 2 indexed citations
5.
Collins, Kyla, Xinxin Yu, Brian A. Droz, et al.. (2023). GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice. Diabetes. 73(2). 292–305. 8 indexed citations
6.
Urva, Shweta, Libbey S. O′Farrell, Yu Du, et al.. (2023). The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obesity and Metabolism. 25(9). 2784–2788. 19 indexed citations
7.
8.
Coşkun, Tamer, Shweta Urva, William C. Roell, et al.. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 34(9). 1234–1247.e9. 180 indexed citations breakdown →
9.
Coghlan, Matthew P., Libbey S. O′Farrell, Aaron D. Showalter, et al.. (2021). 639-P: GIP Receptor Agonism Enhances Weight Loss from Either a Biased or an Unbiased GLP-1 Receptor Agonist in DIO Mice. Diabetes. 70(Supplement_1). 2 indexed citations
10.
Coşkun, Tamer, Julie S. Moyers, William C. Roell, et al.. (2021). 679-P: The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes. Diabetes. 70(Supplement_1). 9 indexed citations
11.
12.
Antonellis, Patrick J., Brian A. Droz, Richard Cosgrove, et al.. (2019). The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. Molecular Metabolism. 30. 131–139. 30 indexed citations
13.
Li, Yongguo, Monja Willershäuser, Josefine Reber, et al.. (2018). Secretin-Activated Brown Fat Mediates Prandial Thermogenesis to Induce Satiation. Cell. 175(6). 1561–1574.e12. 167 indexed citations
14.
O′Farrell, Libbey S., et al.. (2015). Fully Implantable Arterial Blood Glucose Device for Metabolic Research Applications in Rats for Two Months. Journal of Diabetes Science and Technology. 9(4). 771–781. 17 indexed citations
15.
Adams, Andrew C., Tamer Coşkun, Christine C. Cheng, et al.. (2013). Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones. Molecular Metabolism. 2(3). 205–214. 68 indexed citations
16.
Coşkun, Tamer, Libbey S. O′Farrell, Samreen K. Syed, et al.. (2012). Activation of Prostaglandin E Receptor 4 Triggers Secretion of Gut Hormone Peptides GLP-1, GLP-2, and PYY. Endocrinology. 154(1). 45–53. 16 indexed citations
17.
Jesudason, Cynthia D., James E. Baker, Libbey S. O′Farrell, et al.. (2011). Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Medicinal Chemistry Letters. 2(8). 583–586. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph R. Chabenne Breakdown of academic impact, for papers by Sirel Gurbuz Breakdown of academic impact, for papers by Joanna Van Breakdown of academic impact, for papers by Sarah Farr Breakdown of academic impact, for papers by R. Troke Breakdown of academic impact, for papers by Elizabeth Zieliński Breakdown of academic impact, for papers by Lene Jessen Breakdown of academic impact, for papers by Todd M. Suter Breakdown of academic impact, for papers by Jennifer Athanacio Breakdown of academic impact, for papers by Ann-Marie Richard
Rankless by CCL
2026